Concord Drugs Limited (BOM:538965)
India · Delayed Price · Currency is INR 67.93
-2.07 (-2.96%)
At close: Jul 27, 2026
Concord Drugs Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 10.55 | 3.36 | 4.72 | 9.86 | 15.94 |
Depreciation & Amortization | 13.67 | 14.31 | 15.55 | 16.26 | 17.65 |
Other Operating Activities | 16.78 | 21.65 | 17.95 | 15.16 | 13.84 |
Change in Accounts Receivable | -107.77 | -8.75 | -40.17 | 128.79 | -21.3 |
Change in Inventory | -2.47 | -23.46 | -28.58 | -6.86 | -56.18 |
Change in Accounts Payable | -5.74 | 43.64 | -18.35 | -85.48 | 40.31 |
Change in Income Taxes | 2.08 | -0.18 | -1.58 | -3.24 | 2.01 |
Change in Other Net Operating Assets | 5.25 | -13.35 | 58.37 | -57.85 | -4.52 |
Operating Cash Flow | -67.66 | 37.22 | 7.92 | 16.63 | 7.74 |
Operating Cash Flow Growth | - | 369.77% | -52.36% | 114.81% | 4778912.35% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -11.67 | -23.33 | -10.18 | -8.57 | -24.56 |
Cash Acquisitions | - | - | - | -14.15 | - |
Investment in Securities | 0.34 | 0.14 | 0.09 | 0.06 | - |
Other Investing Activities | - | 0 | - | - | 0.12 |
Investing Cash Flow | -11.33 | -23.18 | -10.09 | -22.66 | -24.44 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | - | 17.23 | - | 47.3 |
Long-Term Debt Issued | 4.82 | 6.79 | - | - | - |
Total Debt Issued | 4.82 | 6.79 | 17.23 | - | 47.3 |
Short-Term Debt Repaid | -40.75 | -0.8 | - | -1.56 | - |
Long-Term Debt Repaid | - | - | -12.66 | -0.35 | -12.69 |
Total Debt Repaid | -40.75 | -0.8 | -12.66 | -1.9 | -12.69 |
Net Debt Issued (Repaid) | -35.93 | 5.99 | 4.57 | -1.9 | 34.61 |
Issuance of Common Stock | 31.75 | - | 6.85 | 18.87 | - |
Other Financing Activities | 84.74 | -20.27 | -8.58 | -10.72 | -17.83 |
Financing Cash Flow | 80.56 | -14.28 | 2.83 | 6.24 | 16.79 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash Flow | 1.57 | -0.25 | 0.67 | 0.21 | 0.09 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -79.33 | 13.89 | -2.26 | 8.06 | -16.82 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -10.08% | 3.07% | -0.50% | 1.55% | -2.85% |
Free Cash Flow Per Share | -7.14 | 1.39 | -0.23 | 0.87 | -1.92 |
Levered Free Cash Flow | -108.21 | 5.23 | 45.42 | -22.88 | -31.95 |
Unlevered Free Cash Flow | -97.5 | 17.22 | 56.77 | -12.67 | -22.08 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 17.14 | 20.27 | 18.68 | 16.37 | 14.13 |
Cash Income Tax Paid | 4.2 | 2.03 | 2.2 | 3.79 | 6.71 |
Change in Working Capital | -108.65 | -2.1 | -30.3 | -24.64 | -39.68 |